Press Release
MGEN$1.14 $ + 0.62 (118.62%)
miRagen Therapeutics, Inc. Announces Acquisition of Viridian Therapeutics, Inc.
Company Release - 10/28/2020
Acquisition includes clinical stage anti-IGF-1R monoclonal antibody, VRDN-001, intended for the treatment of thyroid eye disease (TED)
Company plans to use private placement financing proceeds of $91 million to advance multiple compounds through phase 2 proof of concept studies in TED and to expand its orphan disease pipeline
Conference Call and Webcast today at 9 :00 a.m. EDT